Company profile: Synaptogenix
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies in development for neurodegenerative diseases, using bryostatin to promote neuronal health and synaptic regeneration.
Products and services
- Bryostatin: Pharmacological-grade compound leveraged to develop therapies that promote neuronal health and synaptic regeneration specifically for neurodegenerative diseases, serving as a core agent in Synaptogenix’s clinical-stage programs
- Neurodegenerative Therapy Programs: Clinical-stage development initiatives that create novel therapies for neurodegenerative diseases, emphasizing promotion of neuronal health and synaptic regeneration during candidate development
- Synaptic Regeneration Research: Research-grade initiatives advancing the promotion of neuronal health and synaptic regeneration to underpin development of therapies addressing neurodegenerative diseases within the company’s clinical-stage efforts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Synaptogenix
Actimis Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics for respiratory and inflammatory disorders; a start-up biopharmaceutical company spun off from Bayer Healthcare AG's respiratory diseases therapeutic research portfolio, founded by Dr. Kevin Bacon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actimis Pharmaceuticals company profile →
Bristol Myers Squibb
HQ: United States
Website
- Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bristol Myers Squibb company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Shire
HQ: Ireland
Website
- Description: Provider of biotechnology products focused on serving people with rare diseases, supported by a global sales and marketing infrastructure. Offers a broad portfolio with direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy, and Spain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shire company profile →
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Synaptogenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Synaptogenix
2.2 - Growth funds investing in similar companies to Synaptogenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Synaptogenix
4.2 - Public trading comparable groups for Synaptogenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →